Drug Profile
Vatelizumab
Alternative Names: CHR-1103; GBR 500; SAR 339658; TMC-2003; UNII-A4R7G50030Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Chromos Molecular Systems
- Developer Glenmark Pharmaceuticals S.A.; Sanofi
- Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; Cell adhesion molecule inhibitors; Immunosuppressants; Integrin alpha2beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders
Highest Development Phases
- No development reported Cancer
- Discontinued Chronic obstructive pulmonary disease; Multiple sclerosis; Retinal disorders; Rheumatoid arthritis; Ulcerative colitis
Most Recent Events
- 12 Jul 2016 Sanofi terminates a phase II/III trial in Multiple sclerosis based on the planned interim analysis (NCT02222948)
- 01 Jan 2016 Vatelizumab is available for licensing as of 01 Jan 2016. http://www.glenmarkpharma.com/GLN_NWS/homepage.aspx?res=P_GLN
- 31 Dec 2015 Sanofi terminates its licence to develop vatelizumab for Multiple sclerosis